Acknowledgement
Supported by : Ministry of Health & Welfare
References
- Blair HA and Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015;75:91-100. https://doi.org/10.1007/s40265-014-0331-4
- World Health Organization. Global tuberculosis report 2016. http://www.who.int/tb/publications/global_report/en (Updated on Jun 2016).
- Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60. https://doi.org/10.1056/NEJMoa1112433
- Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466. https://doi.org/10.1371/journal.pmed.0030466
- Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015;59:5316-23. https://doi.org/10.1128/AAC.00308-15
- Feuerriegel S, Koser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, et al. Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011;55:5718-22. https://doi.org/10.1128/AAC.05500-11
- Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7. https://doi.org/10.1126/science.1106753
- Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007;51:4202-4. https://doi.org/10.1128/AAC.00181-07
- Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014;9:e102135. https://doi.org/10.1371/journal.pone.0102135
- Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010;54:1022-8. https://doi.org/10.1128/AAC.01611-09
- Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013;68:4-11. https://doi.org/10.1093/jac/dks354
- Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159-68. https://doi.org/10.1086/345744
- Hillemann D, Rusch-Gerdes S, Richter E. In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob Agents Chemother 2008;52:800-1. https://doi.org/10.1128/AAC.01189-07
- Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, et al. rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 2012;56:2743-5. https://doi.org/10.1128/AAC.06227-11
- Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, et al. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtiter assay and the BACTECTM MGITTM 960 system. J Antimicrob Chemother 2016;71:1532-9. https://doi.org/10.1093/jac/dkw044
- Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, et al. A multilaboratory, multicountry study to determine bedaquiline minimal inhibitory concentration quality control ranges for phenotypic drug-susceptibility testing. J Clin Microbiol 2016;54:2956-62. https://doi.org/10.1128/JCM.01123-16
- Keller PM, Homke R, Ritter C, Valsesia G, Bloemberg GV, Botteger EC. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother 2015;59:4352-5. https://doi.org/10.1128/AAC.00614-15
- Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, et al. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 2015;373:1986-8. https://doi.org/10.1056/NEJMc1505196
- Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 2008;52:2226-7. https://doi.org/10.1128/AAC.00414-07
- Lee SH, Choi HB, Yu SY, Chang UJ, Kim CK, Kim HJ. Detection of first-line anti-tuberculosis drug resistance mutations by allele-specific primer extension on a microsphere-based platform. Ann Lab Med 2015;35: 487-93. https://doi.org/10.3343/alm.2015.35.5.487
- Stinson K, Kurepina N, Venter A, Fujiwara M, Kawasaki M, Timm J, et al. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 2016;60:3316-22. https://doi.org/10.1128/AAC.03014-15
- European Committee on Antimicrobial Susceptibility Testing. Definitions of clinical breakpoints and epidemiological cut-off values. Clinical Breakpoints Table V.7.1. Valid From 2017-03-10. http://www.eucast.org/clinical_breakpoints/ (Updated on Mar 2017).
- CLSI. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 2nd edition. CLSI M24-A2. Wayne, PA: Clinical Laboratory Standards Institute. 2011.
- Segala E, Sougakoff W, Chauffour AN, Jarller V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob Agents Chemother 2012;56:2326-34. https://doi.org/10.1128/AAC.06154-11
- Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother 2016;60:2542-4. https://doi.org/10.1128/AAC.02941-15
Cited by
- Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region vol.74, pp.2, 2018, https://doi.org/10.1093/jac/dky414
- Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran vol.9, pp.2, 2018, https://doi.org/10.3390/jcm9020465
- Drug resistance of M. tuberculosis (historical aspects, current level of knowledge) vol.98, pp.1, 2020, https://doi.org/10.21292/2075-1230-2020-98-1-54-61
- Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis vol.382, pp.10, 2018, https://doi.org/10.1056/nejmoa1901814
- Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment vol.55, pp.None, 2018, https://doi.org/10.1016/j.ebiom.2020.102747
- Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis vol.1, pp.4, 2018, https://doi.org/10.1016/s2666-5247(20)30031-8
- Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains vol.58, pp.11, 2020, https://doi.org/10.1128/jcm.01304-20
- Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme? vol.154, pp.1, 2018, https://doi.org/10.4103/ijmr.ijmr_3537_20
- The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis vol.64, pp.1, 2018, https://doi.org/10.1021/acs.jmedchem.0c01176
- Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis vol.12, pp.None, 2021, https://doi.org/10.3389/fmicb.2021.717045
- Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey vol.82, pp.3, 2018, https://doi.org/10.1016/j.jinf.2021.02.004
- Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis vol.2, pp.11, 2018, https://doi.org/10.1016/s2666-5247(21)00175-0
- Wastewater-Based Surveillance of Antibiotic Resistance Genes Associated with Tuberculosis Treatment Regimen in KwaZulu Natal, South Africa vol.10, pp.11, 2018, https://doi.org/10.3390/antibiotics10111362